TLGS — The Leaders in Global SynergyTLGS GROUPStrategic Consulting & Advisory
Verify & pay safelySearchLoginDiscuss your project →

TLGS services & expertise · Curated intelligence

Healthcare, Pharma & Life Sciences

Healthcare, Pharma & Life Sciences is a critical pillar of India's economy and social infrastructure, overseen by the Ministry of Health & Family Welfare, Ministry of Chemicals & Fertilizers (Pharma division), and NITI Aayog. India is the world's largest supplier of generic medicines, supplying over 20% of global generic drug exports, while domestic health infrastructure is being scaled through Ayushman Bharat and the National Health Mission. Policy direction focuses on universal health coverage, PLI-driven pharma manufacturing, and positioning India as a global hub for medical devices and biologics.

generic-medicinesmedical-devicesuniversal-health-coverageapi-manufacturingayushman-bharatbiotech-biologicsclinical-researchhealth-infrastructure
Request a sector discussion →Explore TLGS servicesHealthcare regulatory practice
7Curated research notes
5Relevant TLGS professionals

Latest intelligence · TLGS Research & Perspective

What is changing. What it means for business.

Projects, policy, technology and commercial law connected to practical business decisions.

All 163 insights →

International technology and investment insight

India–UK technology dialogue: organise the commercial pathway before treating cooperation as a project

The talks identify peaceful civil nuclear, SMR, space and emerging-technology collaboration as areas for further engagement. A credible industrial pipeline requires a defined application, authorised technology rights, qualified counterparties and the relevant approvals—not only a bilateral announcement.

Power, Energy & Renewables
Industry, model and participation detailsPower, Energy & RenewablesManufacturing, MSME & Industrial PolicyDigital, Telecom & ElectronicsHealthcare, Pharma & Life SciencesTrade, Customs & Strategic Supply Chains

Exploratory bilateral discussions · no project award announced

18 October 2026BP-20261013-12
Read the insight →

Healthcare regulatory insight

Prescription-medicine advertising: proposed restrictions extend the compliance discussion across distribution

The Ministry’s draft-policy announcement brings retail, wholesale and distribution licence holders into the proposed prior-sanction framework for Schedule H, H1 and X advertising. Businesses should review communication controls without treating the draft as enacted law.

Healthcare, Pharma & Life SciencesDraft Consultation
Industry, model and participation detailsHealthcare, Pharma & Life SciencesDigital, Telecom & ElectronicsManufacturing, MSME & Industrial PolicyMinistry of Health and Family Welfare · Institution named in the cited development

Draft amendment · consultation linked to public Gazette availability

11 October 2026BP-20261011-11
Read the insight →

Policy and industry intelligence

PRIP innovation funding: early discovery, development and commercialisation routes

The second call introduces a New Discovery route for startup and MSME drug-innovation portfolios.

Healthcare, Pharma & Life SciencesDated participation record · Innovation funding applications
Industry, model and participation detailsHealthcare, Pharma & Life SciencesFinancial Services, Capital Markets & InsuranceDepartment of Pharmaceuticals · Responsible institution

PRIP second call · Innovation funding applications: Dated participation record · checked 4 October 2026

Institutional cooperation

4 October 2026BP-20261001-10
Read the insight →

Policy and ecosystem insight

NHA’s digital-health launches: governed data and claims infrastructure become a business priority

The new provider-registry, secure-data and claims tools create implementation questions for hospitals, payers and health-technology businesses. The opportunity lies in interoperability, evidence quality, workflow integration and accountable use of data.

Healthcare, Pharma & Life Sciences
Industry, model and participation detailsHealthcare, Pharma & Life SciencesAI, Cybersecurity & Data GovernanceDigital, Telecom & ElectronicsFinancial Services, Capital Markets & InsuranceNational Health Authority · Institution named in source recordNHA · Institution named in source recordIISc Bengaluru · Institution named in source record

Tools and frameworks launched · institution-level implementation

28 September 2026BP-20260927-10
Read the insight →

Executive insight

GST reform: protect cash flow by fixing the operating interpretation

For large enterprises, rate changes, exemptions and process reform become material through credit treatment, contracts, master data and the quality of the compliance record.

Financial Services, Capital Markets & Insurance
Industry, model and participation detailsFinancial Services, Capital Markets & InsuranceManufacturing, MSME & Industrial PolicyHealthcare, Pharma & Life SciencesDigital, Telecom & ElectronicsGovernance & AdminGST Council · Institution named in source recordCBIC · Institution named in source recordMinistry of Finance · Institution named in source recordDepartment of Financial Services · Institution named in source recordGSTN · Institution named in source record

Effective framework · further process-reform watch

17 September 2026
Read the insight →

Bharat Pulse · TLGS Research

Research for this sector

Asset development, implementation milestones and policy context for industry.

Explore sector intelligence →

Procurement conditions are governed by the issuing authority’s notice and amendments.

Engage TLGS

Connect the right expertise with your next decision.

Discuss your requirement →
Financial approvals: Managing Director only. No cash or personal-account payments for TLGS engagements. Verify & pay safely →